SAJE Pharma, LLC is a biopharmaceutical company focused on developing new therapeutic agents that provide significant benefits over available therapies for rare and common diseases with unmet medical needs.
SAJE Pharma started operations in 2011 after obtaining an exclusive license to innovative technology that targets the last and controlling step in the nitrosylation signal transduction pathway that regulates many therapeutically important cellular responses.
With management and advisors very experienced with nitrosylation research and development, SAJE Pharma is positioned to be a leader in the development of a new therapy for idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases. Since our drugs regulate the evolutionarily conserved nitrosylation signal transduction system used for stabilizing cell physiology, it has applications in many other diseases, some of which we are pursuing.
The SAJE team has over 125 years of in depth drug research and development expertise from discovery chemistry to regulatory filings. This broad range of expertise enables SAJE to move development projects forward that provide the greatest potential for clinical benefit and success. It is the goal of SAJE Pharma to manage our programs through the early phases of clinical development thereby building company value with novel therapies.